Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INVA NASDAQ:MNKD NASDAQ:XOMA NASDAQ:XOMAO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINVAInnoviva$18.63+2.5%$19.95$16.67▼$22.00$1.14B0.38785,688 shs984,244 shsMNKDMannKind$3.75-0.8%$3.91$3.51▼$7.63$1.15B1.022.42 million shs2.54 million shsXOMAXOMA Royalty$24.77-0.4%$25.71$18.35▼$35.00$297.74M0.9335,060 shs20,821 shsXOMAOXOMA$25.25-1.7%$25.39$23.32▼$25.87N/AN/A2,975 shs3,635 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINVAInnoviva+2.53%-0.48%-3.97%-0.48%-1.11%MNKDMannKind-0.79%-7.64%+3.59%-25.00%-34.90%XOMAXOMA Royalty-0.44%-4.10%-5.13%+1.85%-7.44%XOMAOXOMA-1.75%-1.52%-1.15%+0.18%-0.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINVAInnoviva4.1878 of 5 stars3.51.00.04.22.41.71.9MNKDMannKind3.3004 of 5 stars3.63.00.00.01.91.71.9XOMAXOMA Royalty3.9209 of 5 stars3.54.00.03.00.62.50.6XOMAOXOMAN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINVAInnoviva 3.00Buy$40.33116.50% UpsideMNKDMannKind 3.25Buy$9.86162.86% UpsideXOMAXOMA Royalty 3.00Buy$69.50180.58% UpsideXOMAOXOMA 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest XOMA, XOMAO, INVA, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $8.007/16/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.007/11/2025INVAInnovivaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$26.005/28/2025XOMAXOMA RoyaltyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINVAInnoviva$358.71M3.26$3.52 per share5.30$11.03 per share1.69MNKDMannKind$285.50M3.99$0.14 per share27.24($0.29) per share-12.93XOMAXOMA Royalty$13.05M22.72N/AN/A$6.95 per share3.56XOMAOXOMA$13.05MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINVAInnoviva$23.39M-$1.01N/A12.02N/A-16.15%15.77%8.41%N/AMNKDMannKind$27.59M$0.1037.5016.30N/A10.12%-32.41%10.85%8/6/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.15N/AN/AN/A-13.04%-12.43%-4.85%8/12/2025 (Estimated)XOMAOXOMAN/AN/A0.00∞N/AN/AN/AN/A8/11/2025 (Estimated)Latest XOMA, XOMAO, INVA, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025XOMAXOMA Royalty-$0.12N/AN/AN/A$9.39 millionN/A8/6/2025Q2 2025MNKDMannKind$0.04N/AN/AN/A$77.82 millionN/A5/13/2025Q1 2025XOMAXOMA Royalty-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINVAInnovivaN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/AXOMAOXOMA$2.098.28%N/AN/AN/ALatest XOMA, XOMAO, INVA, and MNKD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/21/2025XOMAOXOMAQuarterly$0.52348.28%7/3/20257/3/20257/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINVAInnoviva0.402.482.30MNKDMannKindN/A2.362.11XOMAXOMA Royalty1.185.545.54XOMAOXOMAN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINVAInnoviva99.12%MNKDMannKind49.55%XOMAXOMA Royalty95.92%XOMAOXOMAN/AInsider OwnershipCompanyInsider OwnershipINVAInnoviva2.25%MNKDMannKind2.70%XOMAXOMA Royalty9.10%XOMAOXOMAN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINVAInnoviva10062.78 million61.36 millionOptionableMNKDMannKind400303.93 million295.73 millionOptionableXOMAXOMA Royalty1011.97 million10.88 millionOptionableXOMAOXOMA10N/AN/ANot OptionableXOMA, XOMAO, INVA, and MNKD HeadlinesRecent News About These CompaniesXOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? - NasdaqJune 26, 2025 | nasdaq.comWhy XOMA Royalty Corporation’s (XOMA) Stock Is Down 5.18%May 1, 2025 | aaii.comAXOMA Royalty Stock Dividends | NASDAQ:XOMAO | BenzingaApril 22, 2025 | benzinga.comXoma completes sale of Kinnate Pipeline assets for up to $270MApril 15, 2025 | markets.businessinsider.comBig moves by small biotechs signal potential shift for investorsApril 15, 2025 | bizjournals.comXOMA Royalty Corporation's (NASDAQ:XOMA) Path To ProfitabilityApril 15, 2025 | finance.yahoo.comThe Analyst Verdict: XOMA Royalty In The Eyes Of 4 ExpertsMarch 28, 2025 | benzinga.comXOMA Royalty Corporation: XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business AchievementsMarch 18, 2025 | finanznachrichten.deXoma reports Q4 net loss $4M vs net loss $20.1M last yearMarch 17, 2025 | markets.businessinsider.comXOMA Royalty Corporation's (NASDAQ:XOMA) largest shareholders are retail investors with 38% ownership, institutions own 36%March 2, 2025 | finance.yahoo.comXoma price target lowered to $104 from $123 at H.C. WainwrightFebruary 3, 2025 | markets.businessinsider.comXOMA stock price target cut to $104 by H.C. WainwrightFebruary 3, 2025 | msn.comForecasting The Future: 5 Analyst Projections For XOMA RoyaltyFebruary 3, 2025 | benzinga.com(XOMAO) Trading AdviceNovember 26, 2024 | news.stocktradersdaily.comN(XOMA) On The My Stocks PageOctober 25, 2024 | news.stocktradersdaily.comN(XOMAP) On The My Stocks PageSeptember 25, 2024 | news.stocktradersdaily.comNXOMA gets grant for antibodies targeting transforming growth factor beta (tgfß)September 24, 2024 | pharmaceutical-technology.comPXOMA Royalty CorpSeptember 18, 2024 | morningstar.comMXOMA Royalty Corporation (XOMAO)August 27, 2024 | finance.yahoo.comVirtus.pro vs Zero Tenacity Prediction: Virtus.pro is above their opponentAugust 24, 2024 | telecomasia.netTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXOMA, XOMAO, INVA, and MNKD Company DescriptionsInnoviva NASDAQ:INVA$18.63 +0.46 (+2.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$18.63 0.00 (0.00%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.MannKind NASDAQ:MNKD$3.75 -0.03 (-0.79%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.80 +0.06 (+1.47%) As of 08/1/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.XOMA Royalty NASDAQ:XOMA$24.77 -0.11 (-0.44%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$24.73 -0.04 (-0.16%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.XOMA NASDAQ:XOMAO$25.25 -0.43 (-1.67%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$25.42 +0.16 (+0.65%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
